SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : The Financial Collapse of 2001 Unwinding
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Snowshoe who wrote (7332)2/24/2021 8:14:14 PM
From: Elroy Jetson  Read Replies (2) of 13784
 
Novavax vaccine (a mere recombinant spike protein only with adjuvant) is:

96% effective against infection by the prototype SARS-COV-2 from Wuhan,

86% effective against the UK (and likely the California) variant, and

60% effective in preventing infection with the South African variant.


We now know prior infection with prototype SARS-COV-2 is not protective against infection by the South African variant or as you mentioned against the Brazilian variants.

Novavax, which requires only normal refrigeration and by far the smalled amount of vaccine, will apply for approval in the US in April.

Few or none expected this vaccine to be far more effective than Johnson&Johnson and AstraZeneca's vaccines, but it's at least as effective as Pfizer and Moderna with fairly low-tech technology.


Being a recombinant protein, Novavax will probably be the quickest to market with specific vaccines against new SARS-COV-2 variants.

Novavax expects to begin testing their new vaccine targeting the South African variant next month. Novavax hopes to combine their Influenza and SARS-COV-2 vaccines into one combined product. - washingtonpost.com


No cases of the very deadly SARS-COV-1, which emerged in China in 2002, have been found since 2004. That's the sort of extermination we'd hope to see with SARS-COV-2.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News